Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.81 |
| ▸ | PDE4C | Q08493 | 19/20 | 0.81 |
| ▸ | PDE4A | P27815 | 13/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.81 |
| ▸ | HTR2B | P41595 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767503 | 1.00 | PDE4B (0.81) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL540336 | 1.00 | PDE4B (0.81) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Hydrochloric Acid SCHEMBL537210 | 0.99 | PDE4B (0.80) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Hydrochloric Acid SCHEMBL537316 | 0.99 | PDE4B (0.80) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Hydrochloric Acid SCHEMBL537053 | 0.99 | PDE4B (0.80) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Hydrochloric Acid SCHEMBL1582972 | 0.98 | PDE4B (0.79) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Hydrochloric Acid SCHEMBL537209 | 0.98 | PDE4B (0.79) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Hydrochloric Acid SCHEMBL537315 | 0.98 | PDE4B (0.79) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1582625 | 0.94 | PDE4B (0.71) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Hydrochloric Acid SCHEMBL537237 | 0.94 | PDE4B (0.70) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | AMGEN INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180318257-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION | 2018-11-08 | — | — | US | disclosed |
| EP-2583098-B1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORP (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | NEW YORK UNIVERSITY | 2017-03-30 | — | — | US | disclosed |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-9408831-B2 | Methods for treating respiratory viral infection | CELGENE CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2818164-A1 | Methods of using and compositions comprising PDE4-modulators for treatment, prevention and management of tuberculosis | CELGENE CORPORATION (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2583098-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20080213213-A1 | Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione | CELGENE CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1838294-A1 | COMPOSITIONS COMPRISING PDE4 MODULATORS AND THEIR USE FOR THE TREATMENT OR PREVENTION OF AIRWAY INFLAMMATION | CELGENE CORPORATION (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070207121-A1 | Methods of Using and Compositions Comprising Selective Cytokine Inhibitory Drugs for Treatment and Management of Macular Degeneration | CELGENE CORPORATION | 2007-09-06 | — | — | US | disclosed |
| US-20070190070-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | CELGENE CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070161696-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | CELGENE CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20060148882-A1 | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management airway inflammation | ZELDIS JEROME B | 2006-07-06 | — | — | US | disclosed |
| WO-2006065814-A1 | COMPOSITIONS COMPRISING PDE4 MODULATORS AND THEIR USE FOR THE TREATMENT OR PREVENTION OF AIRWAY INFLAMMATION | CELGENE CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060106085-A1 | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury | CELGENE CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20050239867-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension | CELGENE CORPORATION | 2005-10-27 | — | — | US | disclosed |
| US-20050142104-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders | CELGENE CORPORATION | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190070-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | IL2, IL6, BDNF | PDE4B 1668/4885PDE4C 1599/4885PDE4A 1445/4885 |
| US-20050142104-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4C 8/4885PDE4A 1/4885 |
| US-20050239867-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4C 8/4885PDE4A 1/4885 |
| US-20080213213-A1 | Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione | IL2, MCL1, IL1A | PDE4B 4103/4885PDE4C 4009/4885PDE4A 3583/4885 |
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | PDE4A, PDE4B, IL4 | PDE4B 2/4885PDE4C 4/4885PDE4A 1/4885 |
| US-20060148882-A1 | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management airway inflammation | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4C 6/4885PDE4A 1/4885 |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4C 3/4885PDE4A 1/4885 |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4C 4/4885PDE4A 1/4885 |
| US-20060106085-A1 | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4C 3/4885PDE4A 1/4885 |
| US-20070207121-A1 | Methods of Using and Compositions Comprising Selective Cytokine Inhibitory Drugs for Treatment and Management of Macular Degeneration | IL2, IL6, IL1B | PDE4B 348/4885PDE4C 352/4885PDE4A 295/4885 |
| US-20180318257-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4C 5/4885PDE4A 1/4885 |
| US-20070161696-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | IL6, IL2, IL6ST | PDE4B 561/4885PDE4C 612/4885PDE4A 498/4885 |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4C 5/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.